Brian Orelli

Should Investors Be Worried About Shorts Attacking Clover Health?

Brian Orelli, PhD and Keith Speights | Feb 24, 2021

It's too early to know who's right.

---

Here's Why Bristol Myers Squibb Is Making A Mistake With Its Cash

Brian Orelli, PhD and Keith Speights | Feb 24, 2021

Boosting its pipeline could have a bigger effect on the earnings line.

---

Pfizer Has Gotten Better at Developing Drugs. Here's Why

Brian Orelli, PhD and Keith Speights | Feb 24, 2021

The pharma giant is setting itself up for success, although a little luck also helps.

---

There's More to Merck's New 'Bean Counter' CEO Than First Appears

Brian Orelli, PhD and Keith Speights | Feb 24, 2021

The former chief financial officer has some experience in operations as well.

---

Bristol Myers Is Taking Full Advantage of its Celgene Acquisition

Brian Orelli, PhD and Keith Speights | Feb 24, 2021

The acquisition is adding to both top- and bottom-line growth.

Here's Why Editas Medicine Dropped Today

Brian Orelli, PhD | Feb 23, 2021

After a huge run-up in valuation, investors are a little spooked.

---

What Should Vertex Pharmaceuticals Buy With its $6.6 Billion Stash?

Brian Orelli, PhD and Keith Speights | Feb 20, 2021

The biotech is looking for late-sage drugs to fuel future growth.

---

Here's Why Vertex Pharmaceuticals' Fourth Quarter Was Better Than It First Appeared

Brian Orelli, PhD and Keith Speights | Feb 19, 2021

The biotech's revenue and earnings growth were better than the reported results.

---

Vir Biotechnology and GlaxoSmithKline Expand Their Partnership

Brian Orelli, PhD | Feb 17, 2021

The biotech will get $345 million through an upfront payment and equity investment.

---

Moderna Hits a Short-Term Vaccine Manufacturing Delay, Still on Track for First 100 Million Doses by End of March

Brian Orelli, PhD | Feb 16, 2021

Manufacturing capacity is increasing dramatically despite the short-term issue.

Coronavirus Vaccine Allergic Reactions: Red Flag or Par for the Course?

Brian Orelli, PhD | Feb 12, 2021

For now, they're a statistical anomaly.

---

Can Coronavirus Antibodies Overcome Their Obstacles?

Brian Orelli, PhD and Keith Speights | Feb 12, 2021

Issues with timing, delivery, and manufacturing make the treatments less promising.

---

Sorrento Therapeutics Reports Promising Data From an Uncontrolled Clinical Trial

Brian Orelli, PhD and Keith Speights | Feb 12, 2021

Investors should be cautious until the biotech has data from a controlled study.

---

Is the FDA Delay Actually Good News for Biogen's Alzheimer's Drug?

Brian Orelli, PhD and Keith Speights | Feb 12, 2021

The lack of a quick rejection could be a good sign for the drug's prospects.

---

Can COVID Vaccine Makers Benefit From the Biden Administration?

Brian Orelli, PhD and Keith Speights | Feb 12, 2021

More doses mean more profits, but the companies and the government need to come to a deal.

Novavax Gets the Job Done With its COVID Vaccine

Brian Orelli, PhD and Keith Speights | Feb 11, 2021

It may be behind, but the biotech's clinical trial data looked good.

---

Johnson & Johnson's Coronavirus Vaccine Data Isn't as Bad as It First Appears

Brian Orelli, PhD and Keith Speights | Feb 11, 2021

The company had to worry about more coronavirus variants than the first two authorized vaccines.

---

Vaccines Are Still Protecting Against the Coronavirus Variants (for Now)

Brian Orelli, PhD | Feb 8, 2021

The vaccine makers are still hedging their bets.

---

How Will Biden's Executive Orders Affect Your Healthcare Stocks?

Brian Orelli, PhD | Feb 8, 2021

The decisions could have both short- and long-term implications.

---

Here's Why Seagen Jumped Higher Today

Brian Orelli, PhD | Feb 5, 2021

The rumor mill took hold in late-day trading.